Logout Login Cart iconShop
Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "futcoin fc 26 Besuche die Website Buyfc26coins.com. Kein Stress, super..8Yet"

Looking for quality documents?
external link icon
Repligen Corporation to Present at 11th Annual SVB Leerink Healthcare Conference
WALTHAM, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the 11th Annual SVB Leerink Healthcare Conference being held Feb. 14-18, 2022.  Tony J. Hunt, President and Chief Executive Officer, will participate in a fireside chat on Friday, Feb. 18, at 3:00 p.m. EST. A live webcast of the presentation will be accessible through Repligen’s  Investor Relations website at www.repligen.com , and will be available for replay for a limited period of time following the event. About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs. We are inspiring advances in bioprocessing for the customers we serve; primarily biopharmaceutical drug
external link icon
Repligen Corporation to Present at 40th Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Dec. 30, 2021 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the 40th Annual J.P. Morgan Healthcare conference being held January 10-13.  Tony J. Hunt, President and Chief Executive Officer, will present on Wednesday, January 12, 2022, at 9:45 a.m. EST. A live webcast of the presentation will be accessible through Repligen’s  Investor Relations website at www.repligen.com , and will be available for replay for a limited period of time following the event. About Repligen Corporation Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs. We are inspiring advances in bioprocessing for the customers we serve; primarily biopharmaceutical drug developers and contract
external link icon
Repligen Releases Inaugural Sustainability Report
Sets Baseline and Provides SASB, GRI Core and SDG Disclosures WALTHAM, Mass., Nov. 05, 2021 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ: RGEN) today released its inaugural sustainability report, available on the Company’s website . Repligen’s 2020 Sustainability Report provides an overview of the Company’s environmental, social and governance (ESG) performance in 2020 and into 2021, and provides disclosures aligned to three key reporting frameworks; the Value Reporting Foundation’s SASB Medical Equipment and Supplies Standard, the Global Reporting Initiative (GRI) Standards Core option, and the United Nations (UN) Sustainable Development Goals (SDGs) as informed by the Company’s materiality assessment. As a participant of the United Nations Global Compact (UNGC) since July 2020, this report also serves to fulfill Repligen’s first Communication on Progress (COP) commitment.

The report is built on four pillars that reflect Repligen’s ESG priorities – Principles, People,
external link icon
Repligen Corporation to Present at KeyBanc Life Science and MedTech Investor Forum
WALTHAM, Mass., March 17, 2021 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the KeyBanc Life Science and MedTech Investor Forum being held March 23-24.  Tony Hunt, President & Chief Executive Officer, will participate in a fireside chat on Wednesday, March 24, at 9:15 a.m. EDT. A live webcast of the discussion will be accessible through the  Investor Relations section of the Company’s website, and will be available for replay for a limited period of time following the conference event. About Repligen Corporation Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs. Our primary customers are biopharmaceutical drug developers and contract development and manufacturing
external link icon
Repligen Corporation to Present at Barclays Global Healthcare Conference
WALTHAM, Mass., March 03, 2021 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the Barclays Global Healthcare Conference being held March 9-11. Jon Snodgres, Chief Financial Officer, will participate in a fireside chat on Wednesday, March 10, at 1:50 p.m. EST. A live webcast of the discussion will be accessible through the  Investor Relations section of the Company’s website, and will be available for replay for a limited period of time following the conference event. About Repligen Corporation Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs. Our primary customers are biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our
external link icon
Repligen Corporation to Present at 39th Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the 39th Annual J.P. Morgan Healthcare conference being held January 11-14.  Tony J. Hunt, President and Chief Executive Officer, will make a formal presentation on Wednesday, January 13, at 9:10 a.m. EST. A live webcast of the presentation will be accessible through the  Investor R e lations section of the Company’s website, and will be available for replay for a limited period of time following the conference event. About Repligen Corporation Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs. Our primary customers are biopharmaceutical drug developers and contract development and manufacturing
external link icon
Repligen to Present at Jefferies 2019 Healthcare Conference
WALTHAM, Mass., June 04, 2019 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that Jon K. Snodgres, Chief Financial Officer, will present at the Jefferies 2019 Global Healthcare Conference on Thursday, June 6 at 8:30 a.m. EDT.
A live audio webcast of the presentation will be accessible through the Investor Events section of the Company’s website, and will be available for replay for a limited period of time following the conference event. About Repligen Corporation
Repligen Corporation (NASDAQ:RGEN) is a global bioprocessing company that develops and commercializes highly innovative products that deliver cost and process efficiencies to biological drug manufacturers worldwide. Our portfolio includes filtration products (including XCell™ ATF, TangenX™ SIUS™ TFF and Spectrum KrosFlo™ TFF filters and systems), chromatography products (OPUS® pre-packed columns, chromatography resins,
external link icon
Repligen to Present at the William Blair 2018 Growth Stock Conference
WALTHAM, Mass., May 30, 2018 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a global bioprocessing company focused on the development and commercialization of innovative technologies to improve biopharmaceutical manufacturing processes, today announced that Tony J. Hunt, Chief Executive Officer, will present at the William Blair 2018 Growth Stock Conference. The conference will take place on June 12-14 in Chicago, and the Repligen presentation is scheduled for Wednesday, June 13 at 11:20 a.m. CT.

A live webcast of the presentation will be accessible through the Investor Relations section of Repligen’s website, and will be archived for a period of time following the live event.

About Repligen Corporation
Repligen Corporation (NASDAQ:RGEN) is a global bioprocessing company that develops and commercializes highly innovative products that deliver cost and process efficiencies to biological drug manufacturers worldwide. Our portfolio includes Protein
external link icon
Repligen to Present at Jefferies 2018 Global Healthcare Conference
WALTHAM, Mass., May 23, 2018 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a global bioprocessing company focused on the development and commercialization of highly innovative technologies to improve biopharmaceutical manufacturing processes, today announced that Jon K. Snodgres, Chief Financial Officer, will present at the Jefferies 2018 Global Healthcare Conference. The conference will take place on June 5-8 in New York City, and the Repligen presentation is scheduled for Wednesday, June 6 at 3:00 p.m. EDT. A live webcast of the presentation will be accessible through the Investor Relations section of Repligen’s website, and will be archived for a period of time following the live event.

About Repligen Corporation
Repligen Corporation (NASDAQ:RGEN) is a global bioprocessing company that develops and commercializes highly innovative products that deliver cost and process efficiencies to biological drug manufacturers worldwide. Our portfolio includes Protein
external link icon
Repligen to Participate in 15th Annual Craig-Hallum Institutional Investor Conference
WALTHAM, Mass., May 17, 2018 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a leading life sciences company focused on bioprocessing technology leadership, today announced that Jon K. Snodgres, Chief Financial Officer, will participate in the 15 th Annual Craig-Hallum Institutional Investor Conference, being held on May 30 th in Minneapolis.

The conference is a series of one-on-one meetings with investors and does not include a formal presentation. An updated investor presentation can be accessed on the event date by visiting the Investor Relations section of the Repligen Corporation website at  www.repligen.com.

About Repligen Corporation
Repligen Corporation (NASDAQ:RGEN) is a global bioprocessing company that develops and commercializes highly innovative products that deliver cost and process efficiencies to biological drug manufacturers worldwide. Our portfolio includes Protein products (Protein A affinity ligands, cell culture growth
Close modal

A new look. A better way to explore Repligen.

We’ve redesigned Repligen.com to help you find the right solutions faster, with greater clarity and less effort.

Find what you need faster
Get to the right information with quicker site speed

Explore the site with ease
Navigate easily with an intuitive, simple site structure

Access product details instantly
Find products and resources faster, in fewer clicks

Get support when you need it
Connect with our team when you need support